Bavencio misses in Phase III for third-line gastric cancer

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said PD-L1 mAb Bavencio avelumab missed the primary endpoint in the Phase III JAVELIN Gastric 300 trial

Read the full 244 word article

User Sign In